Navigation Links
Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
Date:11/27/2007

29 presentations on ZEVALIN(R) scheduled at American Society of Hematology

(ASH) Annual Meeting

SEATTLE, Nov. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced it intends to utilize the results of the phase III first-line indolent trial of ZEVALIN (Ibritumomab Tiuxetan), known as the FIT trial, for submission to the United States Food and Drug Administration (FDA) for potential approval in the consolidation of first remissions following chemotherapy for patients with follicular non-Hodgkin's lymphoma (NHL). CTI has signed an agreement to acquire the U.S. marketing, sales and development rights to ZEVALIN, however, that acquisition has not yet been completed and remains subject to closing conditions, including obtaining certain third party consents, and until the transaction is closed, ZEVALIN remains a product and trademark of Biogen Idec, Inc. CTI expects the acquisition to close by the end of November and as such is hosting a booth at the ASH meetings. The results of the FIT trial will be presented in an oral session on Monday, December 10 at 3:30 p.m. (Eastern) at the 49th Annual Meeting of the American Society of Hematology (ASH), being held December 8-11, 2007 in Atlanta.

Bayer Schering recently announced it had submitted the FIT results to the EMEA for consideration for a new indication for the product in the European Union (EU). "With our commercial leadership now on board we look forward to the prospects of working closely with Bayer-Schering in providing the support for the Zevalin brand that this important therapeutic deserves," said James A. Bianco, M.D., President and CEO of CTI.

Other presentations at ASH, includ
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Health Plans Increase Use of Health Incentives
11. Area Health Care Providers Announce Plans to Integrate Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... July 13, 2014 Chromatography system ... components from various types of biological samples such ... the sample mixture into two phase, namely mobile ... mobile phase run over the stationary phase, followed ... components that provide the separation of mixture. Chromatography ...
(Date:7/13/2014)... The report “Micronutrient Market by ... (Chelated & Non Chelated), Application Mode (Soil, Foliar, ... and Forecast to 2018” defines and segments the ... forecasting of the global value and volume for ... restraining factors for the global agriculture micronutrients market ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... noninvasive optical imaging device developed at Cedars-Sinai can ... in the brain and are a classic sign ... investigators conducting a clinical trial in Australia. , ... in an oral presentation at the Alzheimer,s Association ... were invited by conference organizers to participate in ...
Breaking Medicine News(10 mins):Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
... 2 Covaris Incorporated today announced the introduction ... technology.Over the past few years, Covaris instruments have ... as a sample preparation step for next generation ... compatible with all next-gen sequencing platforms. This ...
... on Solidifying Interoperability Standards within HIT Solutions to ... April 2 Greenway Medical Technologies ... health record (EHR), practice management and interoperability solution ... and Management Systems Society (HIMSS) and Integrating the ...
... 2 Despite government efforts to address disparities in ... and Ethnic Health Disparities Initiative, there has been very ... death than Caucasians(1).The statistics are alarming:, ... are 1.6 times more likely to have diabetes than ...
... of alcohol-linked deaths are tied to bouts of excessive consumption, ... drinking in the United States is most common among whites, ... $50,000 or more a year, according to a study released ... or more drinks on one occasion. , The U.S. Centers ...
... of regrowing damaged cardiac tissue, experts say, , , THURSDAY, April ... found that the human heart continues to generate new cardiac ... cell production slows with age. , The finding, published ... open a new path for the treatment of heart diseases ...
... Patients with severe heart failure can be bridged to ... heart pump, according to a just-completed study of the ... reported at the 58th annual meeting of the American ... called a left ventricular assist device (LVAD), is the ...
Cached Medicine News:Health News:Covaris Introduces DNA Shearing Service 2Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 2Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 3Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 4Health News:Health Disparities Among Minority Populations Getting Worse 2Health News:Health Disparities Among Minority Populations Getting Worse 3Health News:Typical Binge Drinker Is Young White Male 2Health News:Human Heart Can Make New Cells 2Health News:Human Heart Can Make New Cells 3Health News:Artificial pump effectively backs up failing hearts 2Health News:Artificial pump effectively backs up failing hearts 3
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
... like all important missions, require ... you to your destination. The ... this dependability. So you can ... intervention and not have to ...
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
Tests for protan and deutan defects. Patients must identify numbers or patterns formed in a matrix of small colored dots varying in color and intensity. Two editions available: 38 plate for detailed ...
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
Medicine Products: